Theresa Raimondo is an Assistant Professor of Engineering, with a secondary appointment in the Division of Biology and Medicine.
Dr. Raimondo’s research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her research primarily focuses on the development of novel lipid nanoparticles (LNPs) for RNA-based therapies, and her work has contributed to the development of adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By using engineering approaches to optimize LNP formulation as well as modulating RNA constructs (sequence and chemical modifications), Dr. Raimondo seeks to both better understand how RNA-LNPs modulate immunity and to use this understanding for the development of new therapies.
Dr. Raimondo obtained a bachelor degree in Chemical and Biochemical Engineering from Brown University, and a doctoral degree in Bioengineering from Harvard University, before becoming a postdoctoral associate at MIT. She has received funding from the American Cancer Society, the DOD Congressionally Directed Medical Research Program, an NIH COBRE, and the MIT Faculty Founders Program. Dr. Raimondo has received a number of awards and honors including the Northeast Bioengineering Conference (NEBEC) Faculty Innovator Award (2024), MIT Faculty Founder Competition Finalist (2023), and Convergence Scholar Fellow through MIT’s Marble Center for Cancer Nanomedicine (2022). She has also been an invited participant of the US Grainger Foundation Frontiers of Engineering – National Academy of Engineering Meeting, been selected to serve on the Early Career Board of ACS Applied Bio Materials (2025 – 2027), and currently serves as the DEI Chair for the Society of Biomaterials Young Scientist Group (2025-2026).
